KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Deferred Revenue (2020 - 2026)

AbCellera Biologics filings provide 7 years of Current Deferred Revenue readings, the most recent being $7.7 million for Q1 2026.

  • Quarterly Current Deferred Revenue fell 76.2% to $7.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Mar 2026, down 76.2% year-over-year, with the annual reading at $17.0 million for FY2025, 11.42% down from the prior year.
  • Current Deferred Revenue hit $7.7 million in Q1 2026 for AbCellera Biologics, down from $17.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $37.2 million in Q1 2023 and bottomed at $7.7 million in Q1 2026.
  • Average Current Deferred Revenue over 5 years is $24.8 million, with a median of $27.2 million recorded in 2023.
  • The largest annual shift saw Current Deferred Revenue surged 98.89% in 2025 before it tumbled 76.2% in 2026.
  • AbCellera Biologics' Current Deferred Revenue stood at $14.3 million in 2022, then surged by 89.88% to $27.2 million in 2023, then dropped by 29.21% to $19.2 million in 2024, then fell by 11.42% to $17.0 million in 2025, then plummeted by 54.52% to $7.7 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Current Deferred Revenue are $7.7 million (Q1 2026), $17.0 million (Q4 2025), and $21.5 million (Q3 2025).